RINEW Randomized Controlled Trial 7-year Follow-up
Launched by UNIVERSITY OF CALIFORNIA, BERKELEY · Jan 29, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The RINEW Randomized Controlled Trial is studying how an early child development program has affected children's growth and learning skills several years after the program ended. Specifically, researchers want to see how the program helped reduce risks for poor development in children during their middle childhood years. This follow-up study will take place about six years after the original program, and they are currently looking for participants to join.
To be eligible for this study, a child's primary caregiver must have been part of the original RINEW trial. The study welcomes children aged between 2 and 3 years old, regardless of gender. Participants can expect to provide information about their child's development and experiences since completing the program. This follow-up could provide valuable insights into how early interventions can shape a child's future.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Child's primary caregiver was enrolled in the RINEW cluster randomized trial
About University Of California, Berkeley
The University of California, Berkeley, a leading research institution renowned for its commitment to scientific innovation and academic excellence, serves as a prominent sponsor of clinical trials aimed at advancing medical knowledge and improving patient outcomes. With a robust infrastructure for interdisciplinary collaboration, UC Berkeley leverages its distinguished faculty, cutting-edge laboratories, and extensive resources to conduct research that addresses critical health challenges. The university is dedicated to fostering a culture of ethical research practices and ensuring the highest standards of safety and efficacy in its clinical investigations, ultimately contributing to the translation of scientific discoveries into tangible health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dhaka, , Bangladesh
Patients applied
Trial Officials
Lia Fernald, PhD
Principal Investigator
University of California, Berkeley
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported